Brian Woodfall - Articles and news items

Janssen Pharmaceuticals Logo

New data from Phase 3 attain study of Janssen’s once-daily simeprevir compared to telaprevir in treatment-experienced adult patients with genotype 1 chronic hepatitis C

Industry news / 19 March 2014 / Janssen

Additional Phase 3 data from the QUEST-1, QUEST-2 and PROMISE studies explore potential of simeprevir in genotype 1 hepatitis C patients while new ATTAIN data demonstrate a superior safety profile for simeprevir…

Janssen Pharmaceuticals Logo

European Commission approves PREZISTA® (darunavir) 800mg tablet once a day

Industry news, News / 16 January 2013 /

The European Commission has approved a new PREZISTA® (darunavir) 800mg tablet…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...